ID: ALA5197008

Max Phase: Preclinical

Molecular Formula: C12H20N6O6S

Molecular Weight: 376.40

Representations

Canonical SMILES:  CC(O)[C@H](NC(=O)N[C@@H](CC(N)=O)c1nnc([C@@H](N)CO)s1)C(=O)O

Standard InChI:  InChI=1S/C12H20N6O6S/c1-4(20)8(11(22)23)16-12(24)15-6(2-7(14)21)10-18-17-9(25-10)5(13)3-19/h4-6,8,19-20H,2-3,13H2,1H3,(H2,14,21)(H,22,23)(H2,15,16,24)/t4?,5-,6-,8-/m0/s1

Standard InChI Key:  ZHZFEBZMBHOQIK-WHFCDURNSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 376.40

Molecular Weight (Monoisotopic): 376.1165

AlogP: -2.42

#Rotatable Bonds: 9

Polar Surface Area: 213.78

Molecular Species: ACID

HBA: 9

HBD: 7

#RO5 Violations: 1

HBA (Lipinski): 12

HBD (Lipinski): 9

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 3.28

CX Basic pKa: 6.84

CX LogP: -6.35

CX LogD: -6.93

Aromatic Rings: 1

Heavy Atoms: 25

QED Weighted: 0.24

Np Likeness Score: -0.39

References

1. Pan C, Yang H, Lu Y, Hu S, Wu Y, He Q, Dong X..  (2021)  Recent advance of peptide-based molecules and nonpeptidic small-molecules modulating PD-1/PD-L1 protein-protein interaction or targeting PD-L1 protein degradation.,  213  [PMID:33454550] [10.1016/j.ejmech.2021.113170]

2. Lin X, Lu X, Luo G, Xiang H..  (2020)  Progress in PD-1/PD-L1 pathway inhibitors: From biomacromolecules to small molecules.,  186  [PMID:31761384] [10.1016/j.ejmech.2019.111876]

Source

Source(1):

• Scientific Literature